Teva closer to win in Allegra patent suit

Jan. 27, 2006 at 5:44 PM

JERUSALEM, Jan. 27 (UPI) -- Teva said Friday it got some good news in its patent lawsuit involving a generic form of Aventis's allergy drug Allegra.

The Israeli company said a New Jersey District Court in its patent lawsuit over Allegra denied a motion for a preliminary injunction brought by Allegra sponsors Sanofi-Aventis Pharmaceuticals and Albany Molecular Research Inc.

The brand drug companies claim Teva is infringing a number of patents covering the antihistamine.

On Sept. 6, Teva and Rockville, Md.-based Barr Laboratories announced they had launched the generic drug, fexofenadine hydrochloride tablets in the United States.

The court's denial of the motion means it was not persuaded that Sanofi-Aventis was likely to prevail at trial.

Barr and Teva have already racked up other victories in the dispute, including the grant of a summary judgment of non-infringement with respect to three patents and a summary judgment of invalidity on an additional patent in the case last April, the company said.

Several patents remain in the litigation, but a trial date has not been set, Teva said.

Follow us on Facebook, Twitter, and Instagram for more news from UPI.com
Related UPI Stories
share with facebook
share with twitter
Trending Stories